Pitavastatin attenuates neuropathic pain induced by partial sciatic nerve in Wistar rats

• Published in: Journal of pharmacy and pharmacology Vol. 75; no. 1; p. 66
• Main Authors: Goel, Radha, Kumar, Nitin, Kumar Saxena, Prasoon, Pratap Singh, Alok, Bana, Sweeti
• Format: Journal Article
• Language: English
• Published: England 31.01.2023
• Subjects: Animals; Hyperalgesia - drug therapy; Hyperalgesia - metabolism; Neuralgia - drug therapy; Neuralgia - metabolism; Rats; Rats, Wistar; Sciatic Nerve; anti-inflammatory; antioxidant; neuropathic pain; PSNL; MAPK; pitavastatin
• ISSN: 2042-7158
• DOI: 10.1093/jpp/rgac079

Pitavastatin is a competitive HMG-CoA reductase inhibitor for lowering of cholesterol level and low density lipoprotein cholesterol. This study was designed to evaluate the effect of pitavastatin in neuropathic pain induced by partial sciatic nerve ligation along with neuronal changes in Wister rats. Pitavastatin was started three days prior to the surgery and continued for 14 days The pain was determined by thermal hyperalgesia and cold allodynia. The biochemical changes were estimated at the end of the study. The levels of cytokines were measured using an ELISA test. Western blot analysis was used to detect levels of expression of JNK, p-JNK, ERK, p-ERK, p38MAPK, p-p38MAPK. The sciatic nerve was investigated histopathologically. Pitavastatin significantly ameliorated nerve pain induced by PSNL and also attenuated the biochemical changes in a dose-dependent manner. The levels of inflammatory mediators were inhibited by pitavastatin. There was significant improvement in sciatic nerve fibres histology. The levels of p-38, p-ERK, and p-JNK and their associated phosphorylated proteins were reduced after treatment with pitavastatin. The present study indicates that treatment with pitavastatin reversed the PSNL-induced neuropathy in Wister rats and may be an additional therapeutic strategy in the management of neuropathic pain.